Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Stem Cells ; 34(10): 2548-2558, 2016 10.
Article in English | MEDLINE | ID: mdl-27352824

ABSTRACT

Stromal support is critical for lung homeostasis and the maintenance of an effective epithelial barrier. Despite this, previous studies have found a positive association between the number of mesenchymal stromal cells (MSCs) isolated from the alveolar compartment and human lung diseases associated with epithelial dysfunction. We hypothesised that bronchoalveolar lavage derived MSCs (BAL-MSCs) are dysfunctional and distinct from resident lung tissue MSCs (LT-MSCs). In this study, we comprehensively interrogated the phenotype and transcriptome of human BAL-MSCs and LT-MSCs. We found that MSCs were rarely recoverable from the alveolar space in healthy humans, but could be readily isolated from lung transplant recipients by bronchoalveolar lavage. BAL-MSCs exhibited a CD90Hi , CD73Hi , CD45Neg , CD105Lo immunophenotype and were bipotent, lacking adipogenic potential. In contrast, MSCs were readily recoverable from healthy human lung tissue and were CD90Hi or Lo , CD73Hi , CD45Neg , CD105Int and had full tri-lineage potential. Transcriptional profiling of the two populations confirmed their status as bona fide MSCs and revealed a high degree of similarity between each other and the archetypal bone-marrow MSC. 105 genes were differentially expressed; 76 of which were increased in BAL-MSCs including genes involved in fibroblast activation, extracellular matrix deposition and tissue remodelling. Finally, we found the fibroblast markers collagen 1A1 and α-smooth muscle actin were increased in BAL-MSCs. Our data suggests that in healthy humans, lung MSCs reside within the tissue, but in disease can differentiate to acquire a profibrotic phenotype and migrate from their in-tissue niche into the alveolar space. Stem Cells 2016;34:2548-2558.


Subject(s)
Healthy Volunteers , Lung/cytology , Mesenchymal Stem Cells/cytology , Pulmonary Alveoli/cytology , Actins/metabolism , Aged , Bronchoalveolar Lavage Fluid , Cell Differentiation , Cell Lineage , Cell Separation , Cluster Analysis , Collagen Type I/genetics , Collagen Type I/metabolism , Collagen Type I, alpha 1 Chain , Colony-Forming Units Assay , Endoglin/metabolism , Female , Flow Cytometry , Fluorescence , Gene Expression Profiling , Humans , Lung Transplantation , Male , Middle Aged , Transcriptome/genetics , Young Adult
2.
Transpl Infect Dis ; 18(2): 302-8, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26781986

ABSTRACT

BACKGROUND: Fungal infection is a common cause of mortality and morbidity in lung transplant recipients (LuTR). Treatment failure to first-line antifungals because of resistance or intolerance is an increasing problem. Posaconazole (PCZ), a triazole antifungal, is an attractive treatment option. METHODS: We performed a single-center retrospective study to describe the use, tolerability, efficacy, and drug interaction effect (with tacrolimus) of PCZ oral suspension in LuTR. RESULTS: Seventy-eight patients were treated with PCZ oral suspension for prophylaxis (n = 15), pre-emptive treatment (n = 31), and treatment of possible (n = 7) and probable (n = 25) invasive fungal infection. A range of fungal isolates was encountered. Resolution was observed in 52.4% (probable, possible, and pre-emptive treatment groups). Aggregate all-cause 1-year mortality was 12.8%. PCZ was well tolerated with 11.5% of patients experiencing adverse effects. Despite dose adjustment strategies, 11.7% of patients experienced supratherapeutic tacrolimus levels, which in 5 cases was associated with a rise (mean 21.6 µmol/L) in serum creatinine. CONCLUSIONS: PCZ is well tolerated and appears effective in the management of fungal infection after lung transplantation. Patients receiving concurrent tacrolimus require careful therapeutic drug monitoring.


Subject(s)
Antifungal Agents/therapeutic use , Immunosuppressive Agents/therapeutic use , Lung Transplantation/adverse effects , Mycoses/drug therapy , Triazoles/therapeutic use , Administration, Oral , Adult , Drug Interactions , Female , Humans , Immunocompromised Host , Immunosuppressive Agents/pharmacokinetics , Male , Middle Aged , Tacrolimus/blood , Tacrolimus/pharmacokinetics , Tacrolimus/therapeutic use , Triazoles/administration & dosage , Young Adult
3.
PLoS One ; 10(8): e0133695, 2015.
Article in English | MEDLINE | ID: mdl-26258716

ABSTRACT

OBJECTIVE: Bronchiectasis (BE) in children is common in some communities including Indigenous children in Australia. Relatively little is known about the nature of systemic inflammation in these children, especially the contribution of specific pro-inflammatory and cytotoxic lymphocyte subsets: T-cells, natural killer (NK) cells and NKT-like cells. We have shown that these cells produce increased cytotoxic (granzyme b and perforin) and inflammatory (IFNγ and TNFα) mediators in several adult chronic lung diseases and hypothesised that similar changes would be evident in children with BE. METHODS: Intracellular cytotoxic mediators perforin and granzyme b and pro-inflammatory cytokines were measured in T cell subsets, NKT-like and NK cells from blood and bronchoalveolar samples from 12 children with BE and 10 aged-matched control children using flow cytometry. RESULTS: There was a significant increase in the percentage of CD8+ T cells and T and NKT-like subsets expressing perforin/granzyme and IFNγ and TNFα in blood in BE compared with controls. There was a further increase in the percentage of pro-inflammatory cytotoxic T cells in Indigenous compared with non-Indigenous children. There was no change in any of these mediators in BAL. CONCLUSIONS: Childhood bronchiectasis is associated with increased systemic pro-inflammatory/cytotoxic lymphocytes in the peripheral blood. Future studies need to examine the extent to which elevated levels of pro-inflammatory cytotoxic cells predict future co-morbidities.


Subject(s)
Bronchiectasis/blood , Inflammation/blood , T-Lymphocytes, Cytotoxic/cytology , Australia , Bronchoalveolar Lavage Fluid , Case-Control Studies , Child , Child, Preschool , Female , Flow Cytometry , Granzymes/blood , Humans , Infant , Interferon-gamma/blood , Interferon-gamma/metabolism , Killer Cells, Natural/cytology , Male , Perforin/blood , Population Groups , T-Lymphocytes/cytology , Tumor Necrosis Factor-alpha/blood , Tumor Necrosis Factor-alpha/metabolism
4.
Eur Respir J ; 37(3): 516-22, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20595148

ABSTRACT

The soluble receptor for advanced glycation end-products (sRAGE) has anti-inflammatory properties, and deficiency of circulating sRAGE is associated with various human diseases. Whether sRAGE concentrations are reduced in chronic obstructive pulmonary disease (COPD) has not been determined. The aim of this study was to determine plasma levels of sRAGE in COPD patients and establish whether sRAGE varies in relation to forced expiratory volume in 1 s (FEV(1)) and other inflammatory markers. 61 COPD patients and 42 healthy controls were recruited. Plasma sRAGE, C-reactive protein (CRP) and serum amyloid A (SAA) were measured in patients with stable COPD. A subgroup had measurements during acute exacerbations of COPD (AECOPD). sRAGE was significantly lower in stable COPD than in healthy controls (p<0.001), while CRP (p<0.001) and SAA (p = 0.015) were higher in stable COPD than in healthy controls. Multiple linear regression confirmed that COPD was negatively associated with sRAGE (p<0.001). Plasma sRAGE was positively correlated with FEV(1) (r(2) = 0.530, p<0.001), while CRP and SAA were inversely proportional to FEV(1). Multiple linear regression analysis showed that only sRAGE was a strong predictor of FEV(1). AECOPD were associated with even lower sRAGE levels that increased with convalescence. Circulating sRAGE is lower in COPD and shows a strong correlation to the degree of airflow limitation.


Subject(s)
Gene Expression Regulation , Glycation End Products, Advanced/metabolism , Pulmonary Disease, Chronic Obstructive/metabolism , Receptor for Advanced Glycation End Products/metabolism , Aged , Biomarkers/metabolism , Case-Control Studies , Female , Forced Expiratory Volume , Humans , Inflammation , Male , Middle Aged , Respiratory Function Tests , Surveys and Questionnaires
5.
Eur Respir J ; 35(1): 64-71, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19643938

ABSTRACT

Anti-viral innate immune responses may be impaired in asthma, although the mechanisms are not well understood. Toll-like receptors (TLRs) 7 and 3 are particularly relevant for initiating responses to common respiratory viruses, as they recognise single-stranded viral RNA and double-stranded viral RNA, respectively. The aim of the present study was to investigate TLR7 and TLR3 function in 14-yr-old adolescents with asthma. Blood mononuclear cells obtained from 17 atopic asthmatics, 29 atopic, non-asthmatics and 21 healthy, non-atopic individuals, were stimulated with the TLR7 agonist imiquimod and the TLR3 agonist poly I:C. Expression of anti-viral molecules was measured by real-time PCR. Concentrations of interferon-gamma-inducible cytokine protein (IP)-10 and interleukin (IL)-6 were measured by ELISA. TLR7-induced myxovirus resistance protein A and 2'5' oligoadenylate synthetase mRNA expression and protein levels of IP-10 were significantly lower in asthma subjects compared with healthy subjects (p = 0.041, p = 0.003 and p = 0.001 respectively). There was a significant negative correlation between total serum immunoglobulin E and IP-10 following TLR7 stimulation. However, TLR3-induced responses did not vary with asthma or atopy. IL-10 mRNA and IL-6 protein synthesis were similar in asthmatic and control subjects. In conclusion, TLR7 function is reduced in adolescents with asthma and this may contribute to susceptibility to respiratory viral infections.


Subject(s)
Asthma/immunology , Toll-Like Receptor 3/physiology , Toll-Like Receptor 7/physiology , Adolescent , Case-Control Studies , Female , Humans , Male , Toll-Like Receptor 3/biosynthesis , Toll-Like Receptor 7/biosynthesis
6.
Immunology ; 91(1): 45-52, 1997 May.
Article in English | MEDLINE | ID: mdl-9203964

ABSTRACT

The roles of the inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1) and IL-12, in murine cytomegalovirus (MCMV) disease were investigated in susceptible BALB/c and resistant C57BL/6 mice. MCMV infection induced IL-1 and TNF-alpha production by peritoneal cells from BALB/c mice, as demonstrated previously in C57BL/6 mice. Overt ill-health and viral replication in the spleens of BALB/c mice were increased by in vivo treatment with soluble TNF-alpha receptors to inhibit the activity of this cytokine, whilst antibodies to IL-12 had a similar but more restricted effect C57BL/6 mice were not affected by either treatment, suggesting TNF-alpha and IL-12 are not critical for natural killer cell-mediated restriction of viral replication in the spleen. Soluble TNF-alpha receptors and antibodies to IL-12 also enhanced MCMV titres and numbers of viral antigen-positive cells in the livers of BALB/c mice and TNF-alpha receptors have similar effects in C57BL/6 livers. In contrast, IL-1 receptors improved the health of MCMV-infected BALB/c mice and reduced viral replication and hepatitis at some time-points. Mechanisms which may underlie these changes are discussed.


Subject(s)
Cytomegalovirus Infections/immunology , Interleukin-12/immunology , Interleukin-1/immunology , Muromegalovirus/immunology , Tumor Necrosis Factor-alpha/immunology , Animals , Cytomegalovirus/physiology , Cytomegalovirus Infections/pathology , Disease Susceptibility , Female , Liver/pathology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Specific Pathogen-Free Organisms , Virus Replication/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...